News May 16, 2019 Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-in-Class PPAR Alpha Antagonist May 08, 2019 Pfizer Acquires Clinical-Stage Biotech Therachon Apr 30, 2019 Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing Feb 14, 2019 Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases Jan 09, 2019 Black Diamond Therapeutics Closes $85 Million Series B Financing Dec 17, 2018 Versant Ventures Raises USD100 Million Canadian Fund Dec 17, 2018 Versant Ventures Raises $700 Million Dec 12, 2018 Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases Dec 11, 2018 Versant Ventures Launches Black Diamond Therapeutics Nov 27, 2018 Genentech Acquires Jecure Therapeutics Nov 13, 2018 Tempest Therapeutics Reports Proof of Mechanism Data for First-in-Class PPAR Alpha Antagonist Oct 31, 2018 Ophthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4 Oct 10, 2018 Gotham Therapeutics Launches with $54 Million Series A Sep 12, 2018 MPM Capital and Versant Ventures Launch CODA Biotherapeutics to Accelerate Development of Chemogenetic Gene Therapy Platform Sep 11, 2018 Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer Sep 04, 2018 Tempest Therapeutics Names Dr. Ginna Laport CMO Jun 25, 2018 Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases May 23, 2018 Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform Apr 12, 2018 Enterprise Therapeutics Raises £29 Million ($41 Million USD) Funding Apr 04, 2018 Inception Neuroscience Program Acquired by Roche Mar 28, 2018 Tempest Therapeutics Closes $70 Million Series B Financing Mar 05, 2018 Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets Feb 27, 2018 Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways Jan 18, 2018 Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs for Autoimmune and Inflammatory Diseases Dec 14, 2017 Jnana Therapeutics Launches With $50 Million Series A Nov 13, 2017 NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model Nov 09, 2017 Northern Biologics Announces CEO Transition Nov 07, 2017 Versant, NEA Back Oyster Point Pharma Nov 06, 2017 NousCom Raises €42 Million Series B Financing Sep 26, 2017 FierceBiotech Names Repare Therapeutics as One of Its “Fierce 15” Biotech Companies of 2017 Sep 26, 2017 FierceBiotech Names Gritstone Oncology as a "Fierce 15" Biotechnology Company of 2017 Sep 07, 2017 Gritstone Oncology Secures $92.7 Million In Series B Financing Jul 25, 2017 VenatoRx Pharmaceuticals Raises $42 Million Series B Jun 22, 2017 Repare Raises US$68M Series A Feb 28, 2017 CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation Feb 15, 2017 Versant Ventures Launches Jecure Therapeutics Feb 07, 2017 Flexion Therapeutics Announces New Drug Application for Zilretta™ (FX006) Accepted by U.S. Food and Drug Administration Feb 02, 2017 Tarveda Therapeutics Raises $30 Million in Series D Financing to Advance Pentarin Miniaturized Drug Conjugates Feb 02, 2017 Vividion Therapeutics, Inc., Launches With $50 Million Series A Financing Jan 05, 2017 Versant Ventures Strengthens Global Team to Launch New $400M Fund Jan 03, 2017 Versant Ventures Closes Sixth Healthcare Fund Dec 19, 2016 Versant Ventures Announces Milestone with Recent Northern Biologics and BlueRock Therapeutics Deals Dec 19, 2016 Northern Biologics, Mosaic Biomedicals Execute Transformative Deal Dec 12, 2016 Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing Nov 02, 2016 Versant Ventures Portfolio Company Turnstone Biologics completes CAD$55.3 million Series B Sep 26, 2016 Nouscom Appoints New Chief Operating Officer and Strengthens the Board of Directors
Nouscom, an oncology company developing patient specific cancer vaccines based on a clinically validated genetic vaccine platform, today announced the appointment of Dr Marina Udier Blagovic as Chief Operating Officer (COO).
Apr 12, 2016 Versant Ventures Strengthens Global Team
Announces Investment Team Promotions and Additions; New Discovery Engine
Media Contact Steve Edelson